Summary
How CGPI maps according to Revere
| Sector Level | Count |
|---|---|
Industries
|
1 |
Sectors
|
2 |
Subsectors
|
4 |
Product/Service Groups
|
7 |
Specific product example for CGPI
| Product Hierarchy |
|---|
Healthcare
|
Biopharmaceuticals
|
Dermatology
|
Acne
|
Rosacea
|
Antibacterial Agents
|
Tetracyclines
|
Company Highlights:
Market Cap.
|
357.739 |
Current Shares Outstnd.
|
21.6 |
| Contact Name | Nancy C. Broadbent |
| Contact Phone | (215)5797388 |
| City, State | Newtown, PA |
| Dividends Per Common Share | 0.00 |
| Dividend Yield | n/a |
SI %SHOUT
|
7.20 |
IH % Shares Outst.
|
74.82% |
| Number of Employees | 147 |
| Revenue Per Employee | 464,265.2 |
| Book Value Per Share | 2.69 |
| 5 Year CAGR in Revenues % | 7.34 |
| 5 Year CAGR in Earnings % | n/a |
Asset Turnover
|
0.22 |
| Fiscal Year End | 12/31/2008 |
| Next Reporting Period | Mar, 2008 |
Business Description:
Chart:
| Last Price | 16.58 |
| Price Chg. | 0.00 |
| Price Chg. % | 0.00% |
| Open Price | n/a |
| High Price | n/a |
| Low Price | n/a |
| 52w High Price | 16.66 |
| 52w Low Price | 7.27 |
| Volume | 0 |
| 30d Avg. Volume | 516,609 |
Competitors by Products
| Products Manufactured/Services Performed/Product Name(s) - Competitors (Tickers)/Product Name(s): |
|---|
Healthcare
|
Biopharmaceuticals
|
Dermatology
|
Acne
|
Rosacea
|
Antibacterial Agents
|
Tetracyclines
Products:
|
Lesion/Scaling Disorders
|
Dermatoses
|
Steroidal Anti-Inflammatory Drugs (SAID)
Products:
Bausch & Lomb Inc. Products:
Bristol Myers Squibb Co. (BMY) Products:
Chattem Inc. (CHTT) Products:
Johnson & Johnson (JNJ) Products:
K-V Pharmaceutical Company (KV/A) Products:
Medicis Pharmaceutical Corporation (MRX) Products:
Perrigo Company (PRGO) Products:
Salix Pharmaceuticals, Ltd. (SLXP) Products:
Sanofi-Aventis SA (ADR) (SNY) Products:
Schering-Plough Corporation (SGP) Products:
Taro Pharmaceutical Industries Ltd. (TAROF) Products:
Teva Pharmaceutical Industries Ltd (ADR) (TEVA) Products:
Watson Pharmaceuticals, Inc. (WPI) Products:
|
Steroidal Anti-Inflammatory Drugs (SAID)/Antibacterial Agents (Antibiotic)
Products:
K-V Pharmaceutical Company (KV/A) Products:
King Pharmaceuticals, Inc. (KG) Products:
Taro Pharmaceutical Industries Ltd. (TAROF) Products:
|
Phase I/Phase II Clinical Stage Products
Products:
Abbott Laboratories (ABT) Products:
Amgen, Inc. (AMGN) Products:
Angiotech Pharmaceuticals, Inc. (USA) (ANPI) Products:
AstraZeneca plc (ADR) (AZN) Products:
Barrier Therapeutics, Inc. (BTRX) Products:
Bayer AG (ADR) (BAYRY) Products:
BioCryst Pharmaceuticals, Inc. (BCRX) Products:
BioSpecifics Technologies Corp. (BSTC) Products:
Bristol Myers Squibb Co. (BMY) Products:
CardioVascular BioTherapeutics, Inc. (CVBT) Products:
CombinatoRx, Incorporated (CRXX) Products:
Critical Therapeutics, Inc. (CRTX) Products:
DUSA Pharmaceuticals, Inc. (DUSA) Products:
Eisai Co., Ltd (ADR) (ESALY) Products:
Eli Lilly & Co. (LLY) Products:
Encysive Pharmaceuticals, Inc. (ENCY) Products:
Genzyme Corporation (GENZ) Products:
GTC Biotherapeutics, Inc. (GTCB) Products:
Hana Biosciences, Inc. (HNAB) Products:
Incyte Corporation (INCY) Products:
Isolagen, Inc. (ILE) Products:
Manhattan Pharmaceuticals, Inc. (MHAN) Products:
Medarex inc. (MEDX) Products:
MiddleBrook Pharmaceuticals, Inc. (MBRK) Products:
Migenix Inc. (MGI:CA) Products:
Mylan Inc. (MYL) Products:
Novadel Pharma Inc (NVD) Products:
Novartis AG (ADR) (NVS) Products:
Novogen Limited (ADR) (NVGN) Products:
NUCRYST Pharmaceuticals Corp. (USA) (NCST) Products:
OrthoLogic Corporation (OLGC) Products:
Pfizer Inc. (PFE) Products:
Pharmacopeia, Inc. (PCOP) Products:
QLT Inc. (USA) (QLTI) Products:
Roche Holding Ltd. (ADR) (RHHBY) Products:
Shire plc (ADR) (SHPGY) Products:
SkyePharma PLC (ADR) (SKYEY) Products:
Teva Pharmaceutical Industries Ltd (ADR) (TEVA) Products:
Vertex Pharmaceuticals Incorporated (VRTX) Products:
Warner Chilcott Ltd. (WCRX) Products:
|
Infectious Diseases
|
Bacterial
|
Antibacterial Agents
|
Narrow Spectrum
|
Digestive System
|
Periodontitis
|
Tetracyclines
Products:
Johnson & Johnson (JNJ) Products:
Lannett Company, Inc. (LCI) Products:
Teva Pharmaceutical Industries Ltd (ADR) (TEVA) Products:
|
Medical Devices
|
Dental
|
Treatment
|
Restorative
|
Guided Tissue Regeneration
|
Membranes
Products:
Kensey Nash Corporation (KNSY) Products:
RTI Biologics Inc. (RTIX) Products:
Zimmer Holdings, Inc. (ZMH) Products:
|
Drug Delivery
|
Transdermal
|
Patches
Products:
3M Company (MMM) Products:
Abbott Laboratories (ABT) Products:
Antares Pharma, Inc. (AIS) Products:
DURECT Corporation (DRRX) Products:
ICU Medical, Incorporated (ICUI) Products:
Johnson & Johnson (JNJ) Products:
Watson Pharmaceuticals, Inc. (WPI) Products:
|
Key Financials
| Period Length/End |
3 months ending 12/31/2007 |
3 months ending 09/30/2007 |
3 months ending 12/31/2006 |
12 months ending 12/31/2007 |
12 months ending 12/31/2006 |
12 months ending 12/31/2005 |
| Total Revenue | 17.0 | 15.9 | 13.2 | 63.6 | 26.4 | 26.4 |
Gross Margin %
|
n/a | n/a | n/a | n/a | n/a | n/a |
Operating Income
|
n/a | n/a | n/a | n/a | n/a | n/a |
Operating Margin %
|
n/a | n/a | n/a | n/a | n/a | n/a |
| Tax Rate % | 0 | 0 | 0 | 0 | 0 | 0 |
| Income After Taxes | 1.0 | -1.1 | -4.8 | -8.8 | -33.4 | -18.8 |
| Net Income Margin % | 5.8 | -6.62 | -36.52 | -13.83 | -126.77 | -71.22 |
F.D. EPS - Incl. Xord. Items
|
0.02 | -0.07 | -0.28 | -0.51 | -1.98 | -1.67 |
| Book Value Per Share | 2.69 | 2.61 | 2.94 | 2.69 | 2.94 | 2.22 |
Ratios
P/R Ratio (TTM)
|
5.63 |
P/E Ratio (TTM)
|
0.00 |
| Price To Free Cash Flow (TTM) | -61.99 |
| Price To Book Value | 6.20 |
| Net Assets to Market Cap. % | 21.06% |
| Beta | 0.26 |
Days to Sell Inventory
|
260.81 |
Current Ratio
|
5.4 |
Quick Ratio
|
5.07 |
| Interest Coverage | n/a |
| Debt to Market Cap. % | 0.00% |
| Return on Equity % | -15.24 |
| Return on Assets % | -11.44 |
| Return on Invested Capital % | -20.73 |